Shanghai ZJ Bio-Tech Co., Ltd (SHA:688317)
China · Delayed Price · Currency is CNY 16.89
-0.34 (-1.97%)
Jun 11, 2026, 3:00 PM CST
Shanghai ZJ Bio-Tech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 114.98 | 121.69 | 175.52 | 270.87 | 2,263 | 1,993 |
Other Revenue | 3.13 | 3.13 | 3.13 | 3.46 | 63.59 | 25.37 |
| 118.1 | 124.82 | 178.65 | 274.33 | 2,326 | 2,019 | |
Revenue Growth (YoY) | -25.98% | -30.13% | -34.88% | -88.21% | 15.23% | -1.62% |
Cost of Revenue | 30.43 | 33.97 | 216.07 | 282.13 | 1,131 | 762.4 |
Gross Profit | 87.67 | 90.85 | -37.42 | -7.8 | 1,196 | 1,256 |
Selling, General & Admin | 123.23 | 130.03 | 151.16 | 184.72 | 341.77 | 262.01 |
Research & Development | 48.88 | 50.87 | 58.78 | 61 | 104.62 | 108.79 |
Other Operating Expenses | 1.88 | 0.75 | 3.63 | 6.2 | 9.07 | 10.46 |
Operating Expenses | 174.38 | 182.04 | 221.98 | 253.27 | 461.8 | 386.64 |
Operating Income | -86.7 | -91.19 | -259.4 | -261.08 | 733.81 | 869.79 |
Interest Expense | -3.49 | -3.49 | -0.34 | -0.35 | -0.46 | - |
Interest & Investment Income | 67.62 | 65.9 | 113.26 | 67.54 | 42.54 | 17.16 |
Currency Exchange Gain (Loss) | -22.65 | -22.65 | 14.38 | 17.82 | 65.8 | -13.86 |
Other Non Operating Income (Expenses) | -23.44 | -4.25 | -2.57 | -1.22 | 1.85 | -3.68 |
EBT Excluding Unusual Items | -68.66 | -55.69 | -134.67 | -177.29 | 843.55 | 869.4 |
Gain (Loss) on Sale of Investments | 2.56 | 2.36 | - | - | - | - |
Gain (Loss) on Sale of Assets | 0.04 | 0.04 | -5.94 | -1.36 | -0.06 | - |
Asset Writedown | 4.29 | - | -16.55 | - | - | -0.03 |
Other Unusual Items | 11.17 | 11.17 | 6.6 | 22.02 | 57.99 | 27 |
Pretax Income | -50.59 | -42.12 | -150.57 | -156.63 | 901.48 | 896.37 |
Income Tax Expense | -6.8 | -7.82 | -23.11 | -19.78 | 141.21 | 137.85 |
Earnings From Continuing Operations | -43.79 | -34.3 | -127.46 | -136.86 | 760.27 | 758.52 |
Net Income | -43.79 | -34.3 | -127.46 | -136.86 | 760.27 | 758.52 |
Net Income to Common | -43.79 | -34.3 | -127.46 | -136.86 | 760.27 | 758.52 |
Net Income Growth | - | - | - | - | 0.23% | -18.61% |
Shares Outstanding (Basic) | 173 | 181 | 190 | 193 | 193 | 191 |
Shares Outstanding (Diluted) | 173 | 181 | 190 | 193 | 193 | 191 |
Shares Change (YoY) | -10.02% | -5.11% | -1.30% | -0.36% | 1.51% | 30.46% |
EPS (Basic) | -0.25 | -0.19 | -0.67 | -0.71 | 3.93 | 3.98 |
EPS (Diluted) | -0.25 | -0.19 | -0.67 | -0.71 | 3.93 | 3.98 |
EPS Growth | - | - | - | - | -1.26% | -37.62% |
Free Cash Flow | 39.22 | 64.86 | 58.1 | -163.03 | 510.41 | 143.88 |
Free Cash Flow Per Share | 0.23 | 0.36 | 0.30 | -0.85 | 2.64 | 0.76 |
Dividend Per Share | - | - | 0.110 | - | 1.200 | 1.365 |
Dividend Growth | - | - | - | - | -12.09% | -14.69% |
Gross Margin | 74.23% | 72.79% | -20.95% | -2.84% | 51.40% | 62.23% |
Operating Margin | -73.41% | -73.06% | -145.20% | -95.17% | 31.55% | 43.08% |
Profit Margin | -37.08% | -27.48% | -71.35% | -49.89% | 32.68% | 37.57% |
Free Cash Flow Margin | 33.21% | 51.96% | 32.52% | -59.43% | 21.94% | 7.13% |
EBITDA | -24.01 | -27.76 | -193.02 | -197.63 | 790.85 | 894.63 |
EBITDA Margin | -20.33% | -22.24% | -108.04% | -72.04% | 34.00% | 44.31% |
D&A For EBITDA | 62.7 | 63.44 | 66.38 | 63.45 | 57.03 | 24.84 |
EBIT | -86.7 | -91.19 | -259.4 | -261.08 | 733.81 | 869.79 |
EBIT Margin | -73.41% | -73.06% | -145.20% | -95.17% | 31.55% | 43.08% |
Effective Tax Rate | - | - | - | - | 15.66% | 15.38% |
Revenue as Reported | 124.82 | 124.82 | 178.65 | 274.33 | 2,326 | 2,019 |